QuantuMDx Raises $8.4M to Support Development of POC MDx Device | GenomeWeb

NEW YORK (GenomeWeb News) – British molecular diagnostics company QuantuMDx has closed an $8.4 million investment round to further the development of a device for point-of-care testing, the firm said today.

Private investors and the University of Newcastle upon Tyne contributed to the round, which will support the optimization of Q-POC, QuantuMDx's handheld DNA sequencing and genotyping device, and allow the company to flesh out its R&D team and advisory board.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: mutations linked to nasopharyngeal carcinoma, salivary proteins common among oral squamous cell carcinoma patients, and more.

At Wired, a science journalist discusses her decision not to undergo BRCA testing.

The Japan Times says regulations are needed to oversee human genome-editing research.

In PLOS this week: molecular surveillance of S. Typhi, genome-wide association study of attention in children, and more.